期刊文献+

原发性胃肠道间质瘤的多因素Cox模型分析 被引量:2

Cox model analysis for multiple factors in prognosis of patients with the primary gastrointestinal stromal tumors
原文传递
导出
摘要 目的分析胃肠道间质瘤(GIST)的临床特征、治疗效果及其影响因素。方法复习216例原发性GIST患者临床资料并加以随访进行Cox回归模型分析。结果全组1、2、3、4、5年生存率分别为94.4%(204/216)、90.2%(129/143)、88.3%(68/77)、87.5%(35/40)和85.0%(17/20)。年龄、肿瘤发生部位、是否完整切除、肿瘤是否破裂、术后是否辅助治疗、是否复发、肿瘤病理核分裂象、最大径等因素对GIST患者生存率的影响有显著性意义(P〈0.05);并且随着影响因素变量值增大,死亡的风险值增高。其中完整切除对患者的预后起着决定性的作用。患者性别、CD117、是否活检、内窥镜下黏膜是否糜烂、手术切缘等对生存率影响无显著性意义(P〉0.05)。术后辅助治疗可明显提高患者生存率,尤其对于高风险度患者。结论GIST仍以外科治疗为主,其手术方式的选择更多取决于肿瘤的部位和大小,完整切除或扩大切除能提高生存率。患者年龄、肿瘤发生部位、是否完整切除、肿瘤是否破裂、是否辅助治疗、术后是否复发、肿瘤病理核分裂象、最大径等是影响预后的重要因素,有利于指导临床规范化治疗。 Objective To analyze the clinical characteristics, effects of adjuvant therapy and influential factors of gastrointestinal stromal tumors (GIST). Methods A retrospective and multiple factor Cox model analysis on 216 cases of primary GIST diagnosed by surgery and pathology was conducted. Results The total survival rates of patients at one to five years were 94.4 % (204/216), 90.2 % (129/143), 88.3 % (68/77), 87.5 % (35/40) and 85.0 % (17/20), respectively. The statistically significant prognostic factors for survival rates of patients with GIST included age, location of tumor, local or total tumor resection, rupture of tumor, adjuvant treatment, recurrence, mitotic rate, and tumor size (P 〈 0.05). Due to those influence factors, the greater of the values, the higher of the risk of death. Among those factors, whether having grass total resection played a decisive role in the prognosis of patients with GIST. Other factors, such as sex, CD,7, biopsies, endoscopic mucosal erosion, and operation cutting margin had no significant relevance with the survival rate of patients (P 〉0.05). Postoperative adjuvant therapy could significantly improve the survival rate of patients with GIST, especially for patients with high risk. Conclusion Surgical treatment should be given priority to treatment of GIST, and the choice of the surgery strategies depends mainly on the location and size of tumors. The complete resection or extensive resection could improve survival rates. Age, location, total tumor resection, rupture of tumor, adjuvant treatment, recurrence, mitotic rate, and tumor size are important factors affecting prognosis and survival rate of patients with GIST, which could guide standardized clinical treatment.
出处 《肿瘤研究与临床》 CAS 2011年第12期796-799,共4页 Cancer Research and Clinic
关键词 胃肠道间质肿瘤 危险因素 预后 比例危险度模型 Gastrointestinal stromal tumors Risk factors Prognosis Proportional hazards models
  • 相关文献

参考文献15

  • 1Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279: 577-580.
  • 2Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer, 2008, 47: 853-859.
  • 3Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromaX tumors. Am J Clin Pathol, 2010, 133: 141- 148.
  • 4Ruka W, Rutkowski P, Szawlowski A, et al. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol. 2009, 35: 87-91.
  • 5Scandinavian Sarcoma Group. Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) . [DB/OL]Clinical Trails. gov. 2005-6-30(2009-2-3)[2012-10- 21]. http://eliniealtrials.gov/show/NCT00116935. Aeeessed on 15 August 2010.
  • 6Miettinen MBJYSLH. Mesenchymal tumours of the stomach.// Hamilton SR AL. World Health Organization classification of tumours Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000: 62-65.
  • 7Agaimy A, Wuensch PH. Gastrointestinal stromal tumours in patients with other-type cancer: a mere coincidence or an etiological association? A studyof97GISTcases. Z Gastroenterol, 2005, 43: 1025-1030.
  • 8Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol, 2006, 37: 1527-1535.
  • 9Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-kit mutations. Am J Surg Pathol, 2007, 31 : 113-120.
  • 10Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39: 1411 - 1419.

二级参考文献30

  • 1娄越亮,陈华,张燮良,战忠利.96例胃肠道间质瘤临床诊治分析[J].中华肿瘤杂志,2004,26(7):437-439. 被引量:25
  • 2林苏,刘懿.胃肠道间质瘤[J].国外医学(消化系疾病分册),2005,25(1):25-28. 被引量:16
  • 3杨其昌,季晓华,沈屹,韩枋,张晓娟,刘宏斌.74例胃肠道间质瘤临床病理与生物学行为评价[J].中华病理学杂志,2005,34(1):6-10. 被引量:68
  • 4席吕刚,蔡端.胃肠道间质瘤35例诊治分析[J].中国实用外科杂志,2005,25(3):151-153. 被引量:27
  • 5Blackstein M, Blay J, Corless C, et al. Gastrointestinal stromal tumours. Consensus Statement on diagnosis and treatment. Can J Gastroentero, 2006, 20: 157-163.
  • 6Debiec-Ry chter M, Sciot R, le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. EORTC Soft Tissue and Bone Sarcoma Group. The Italian Sarcoma Group. Australasian Gastroznlestinal Trails Group. Eur J Cancer, 2006, 42:1093-1113.
  • 7Catena F, Di Battista M, Fusaroli P, et al. Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review. J Gastrointest Surg, 2008, 12: 561-568.
  • 8Santos Fernandes G, Castro Cotti GC, Freitas D, etal. Downstaging of a rectal gastrointestinal stromal tumor by neoadjuvant imatinib therapy allowing for a conservative surgical approach. Clinics, 2009, 64: 819-821.
  • 9DeMatteo RP. Nanoneoadjuvant therapy of gastrointestinal stromal tumor(GIST). Ann Surg Oncol, 2009, 16: 799-800.
  • 10Mazur MT,Clark HB.Gastric stromal tumors.Reappraisal of histogenesis[J].Am J Surg Pathol,1983,7(6):507~519

共引文献50

同被引文献16

  • 1Miettinen M, Lasota J. Gastrointestinal stromal tumors. GastroenterolClin North Am, 2013,42: 399-415.
  • 2Miettinen M, Sohin LH, Lasota J. Gastrointestinal stromal tumors ofthe stomach: a clinicopathologic, immunohistonhemical and moleculargenetic study of 1765 cases with long-term follow-up. Am J SurgPathol, 2005, 29: 52-68.
  • 3Hostein I, Faur N, Primois C, et al. BRFA mutation status ingastrointestinal stromal tumors. Am J Clin Pathol, 2010, 133: 141-148.
  • 4Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinalstromal tumors: a consensus approach. Hum Pathol, 2002, 33: 459-465.
  • 5Cinhoz-Lach H, Kasztelan-Szczerhinska B, Slomka M. Gastrointestinalstromal tumors: epidemiology, clinical picture, diagnosis,prognosis andtreatment.Pol Arnh Med Wewn, 2008, 118: 216-221.
  • 6Hoda KM, Rodriguez SA, Faigel DO. EUS-guided sampling ofsuspected GI stromal tumors. Gastrointest Endosn, 2009, 69: 1218-1213.
  • 7Kiduk J, Gryko M, Guzinska-Ustymowicz K, et aL Immunohistorhemicaldiagnosis of gastrointestinal stromal tumors - an analysis of 80 casesfrom 2004 to 2010. Ariv Clin Exp Med, 2013, 22: 33-39.
  • 8张威,邵钦树,叶再元,赵仲生,王跃东,竺扬文.原发性胃肠道间质瘤73例的外科治疗[J].中华外科杂志,2009,47(2):98-101. 被引量:5
  • 9王贵明,贺杰峰,赵瑛,鲍民生.49例胃肠间质瘤的治疗及预后[J].肿瘤研究与临床,2009,21(12):848-849. 被引量:1
  • 10郭芸,刘大亮.胃肠道间质瘤的CT诊断[J].中国医疗设备,2010,25(6):131-133. 被引量:4

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部